netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Results

Looking for Semaglutide found 12 matches
Open monograph to display formulary status BNF Category
  Semaglutide  (Ozempic®) Endocrine system - GLP1 agonists - 06.01.02.03
  Semaglutide  (Rybelsus®) Endocrine system - GLP1 agonists - 06.01.02.03
  Semaglutide  (Wegovy®) Central nervous system - Anti-obesity drugs acting on the gastro-intestinal tract - 04.05.01
  Semaglutide  (Wegovy®) Endocrine system - GLP1 agonists - 06.01.02.03
  Tirzepatide Endocrine system - GLP1 agonists - 06.01.02.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Medicines Matters Bulletin Issue 25 Rybelsus (oral semaglutide) risk of medication error update October 2025 (06.01.02.03)
link in drug section MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products (06.01.02.03)
link in drug section MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products (06.01.02.03)
link in drug section MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products (04.05.01)
link in drug section NICE TA875: Semaglutide for managing overweight and obesity (06.01.02.03)
link in drug section NICE TA875: Semaglutide for managing overweight and obesity (04.05.01)
link in drug section Rybelsus® (oral semaglutide): risk of medication error due to introduction of new formulation with increased bioavailability (06.01.02.03)




Document Library Items Found

 
netFormulary